Diabetes Drug Cuts Cancer Spread Risk Up to 50%

Twenty million Americans already take GLP-1 drugs like Ozempic and Wegovy for diabetes and weight loss, and now researchers have discovered these medications might help fight cancer too.

A major study from Cleveland Clinic tracked more than 12,000 cancer patients over five years and found something remarkable. Patients taking GLP-1 drugs after their cancer diagnosis were 31% to 50% less likely to see their cancer spread compared to those taking a different diabetes medication.

The results were especially striking for four cancer types. Lung cancer patients saw their risk of cancer spreading drop by half. Breast cancer patients had a 43% lower risk, while colorectal cancer patients saw a 31% reduction and liver cancer patients experienced a 38% decrease.

Dr. Mark David Orland from Cleveland Clinic presented the findings ahead of the American Society of Clinical Oncology annual meeting. The study examined patients with stage I-III cancers who had diabetes, comparing those who started GLP-1 drugs to those who took DPP-4 inhibitors instead.

These drugs were never just about lowering blood sugar. GLP-1 medications have anti-inflammatory properties and appear to affect how the immune system works, which researchers believe might explain the cancer benefits.

Why This Inspires

This discovery matters because cancer spreads are often what make the disease deadly. Finding that an already-approved medication might slow or prevent metastasis could eventually help millions of patients who are fighting cancer while managing diabetes.

The timing is powerful too. As these medications become more widely used for various health conditions beyond diabetes, including heart and kidney disease, scientists are uncovering unexpected benefits that could transform cancer care.

What makes this especially hopeful is that these drugs are already proven safe and available. If future studies confirm these results, doctors won't need to wait years for new treatments to be developed and approved.

Experts emphasize patience, though. ASCO President Dr. Eric Small and other cancer specialists agree the findings are exciting but call for controlled clinical trials before prescribing GLP-1 drugs specifically to prevent cancer spread. They want to make sure the effect is real and not just because patients taking these medications might be more health-conscious overall.

Dr. Julie Gralow, ASCO's chief medical officer, pointed out what makes this study unique. Most research on GLP-1 drugs and cancer has looked at whether they prevent cancer from developing in the first place. This study showed they might help people already diagnosed with cancer.

Researchers are now planning the rigorous trials needed to prove whether GLP-1 drugs directly fight cancer spread. For the millions of cancer patients and survivors living with or at risk for diabetes, these findings offer genuine reason for hope.